Amendment to the Claims

1. (Currently amended) A method for increasing the survival or growth of motoneurons comprising bringing exposing the motoneurons in contact with to a low molecular weight heparin.

2. (Currently amended) A method for treating preventing treating of a motoneuron disease in a patient in need thereof comprising administering to the patient a pharmaceutically effective amount of a low molecular weight heparin.

3. (Original) The method according to claim 2 wherein the motoneuron disease is amyotrophic lateral sclerosis, progressive spinal muscular atrophy, infantile muscular atrophy or lateral sclerosis.

4. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin has a mean molecular weight of between 1000 and 10000 daltons.

5. (Original) The method according to claim 4, wherein the low molecular weight heparin has a mean molecular weight of between 1500 and 6000 daltons.

6. (Original) The method according to claim 4, wherein the low molecular weight heparin has a mean molecular weight of between 4000 and 5000 daltons.

7. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin consists of oligosaccharides having a 2-O-sulfo-4-enopyranosuronic acid at one of their ends.

8. (Canceled) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is obtained by depolymerization of a heparin ester using a base.

9. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is enoxaparin.

10. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is nadroparin.

-2-

11. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is parnaparin.

12. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is reviparin.

13. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is dalteparin.

14. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is tinzaparin.

15. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is danaparoid.

16. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is ardeparin.

17. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is certoparin.

18. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is CY222.

19. (Original) The method according to one of claims 1 to 3, wherein the low molecular weight heparin is SR90107/ORG31540.

USST98048US DIV 1